MI-773 is an MDM2 Inhibitor for Adenoid Cystic Carcinoma Therapy
Adenoid Cystic Carcinoma (ACC) is a rare kind of cancer, occurs in different tissues or organs. It commonly happens in salivary glands, and also exists in breast, lung, brain and…
Adenoid Cystic Carcinoma (ACC) is a rare kind of cancer, occurs in different tissues or organs. It commonly happens in salivary glands, and also exists in breast, lung, brain and…
Chronic myeloid leukemia is a myeloproliferative disorder characterized by the presence of the oncogenic fusion protein BCR-ABL1. ABL1, one of the fusion partners in the BCR-ABL1 protein, contains an allosteric…
BRD4 (Bromodomain-containing protein 4) belongs to the BET family, which also contains BRD2, BRD3, and BRDT. BRD4 has two bromodomains to recognize acetylated lysine residues. They are BD1 and BD2.…
Yesterday, I introduced AMG 232 as a potent, selective and orally available inhibitor of p53-MDM2 interaction. Additionally, we have known the significance of MDM2-p53 interaction in cancer development. Today, I’d…
The p53 tumor suppressor induces cell growth arrest and apoptosis in response to DNA damage or stress. And inactivation of the p53 pathway plays an indispensable role in tumor survival.…
Melanomas were responsible for more than 75% of estimated skin cancer deaths in 2012. And the incidence rate has been increasing for the last 30 years. Additionally, NRAS is the…
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Of these, PPARα mainly expresses in the liver, where it activates fatty acid catabolism.…
Activating mutations in NRAS account for 20%-30% of melanoma. but, there are no effective anti-NRAS therapies. Originally, it reports that the serine/threonine-protein kinase 19 (STK19) phosphorylate a-casein at serine/threonine residues…
Acute leukemia is a neoplastic disease characterized by a rapid accumulation of primitive hematopoietic cells. MPT0B392 acts as a potential anticancer drug for the treatment of acute leukemia. MPT0B392 is…
Myeloid cell leukemia 1 (MCL1) is a prosurvival protein. It overexpresses in a variety of different cancers and is of tremendous therapeutic interest. Furthermore, MCL1 is involved in complex protein−protein…